BNF:

8.1.5

Status:

Red

Decision Date:

None

Comments

RED: NICE TA23 - use of temozolomide for the treatment of recurrent malignant glioma (brain cancer). (TA published April 2001, slight update to technology appraisal - April 2016)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again